Duvelisib, an oral dual PI3K‐δ, γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial. (12th June 2019)

Record Type:: Journal Article
Title:: Duvelisib, an oral dual PI3K‐δ, γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial. (12th June 2019)
Main Title:: Duvelisib, an oral dual PI3K‐δ, γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial
Authors:: Horwitz, S.M.
Foss, F.M.
Porcu, P.
Moskowitz, A.
Mehta‐Shah, N.
Jacobsen, E.
Khodadoust, M.S.
Kim, Y.H.
Weinstock, D.
Lustgarten, S.
Baglio, M.
Youssoufian, H.
Brammer, J.
Abstract:
Is Part Of:: Hematological oncology. Volume 37(2019)Supplement 2
Journal:: Hematological oncology
Issue:: Volume 37(2019)Supplement 2
Issue Display:: Volume 37, Issue 2 (2019)
Year:: 2019
Volume:: 37
Issue:: 2
Issue Sort Value:: 2019-0037-0002-0000
Page Start:: 65
Page End:: 66
Publication Date:: 2019-06-12
Subjects:: Hematological oncology -- Periodicals
Hematology
Medical Oncology
616.99418005
Journal URLs:: http://onlinelibrary.wiley.com/ ↗
DOI:: 10.1002/hon.33_2629 ↗
Languages:: English
ISSNs:: 0278-0232
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 4291.550000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 12428.xml